The Hunter Williams Podcast The ARA-290 Masterclass | A Complete Research Guide (2026)
Sep 22, 2026
ARA-290 stands out among experimental peptides for its randomized human research on nerve-fiber regrowth. This deep dive explores its origins in EPO, potential applications for diabetic and small-fiber neuropathy, safety limits, dosing, cycling, injection technique, and sequencing with BPC-157 or TB-500. It also examines when nerve compression, long COVID, or general recovery fall outside its reach.
AI Snips
Chapters
Transcript
Episode notes
ARA-290 Has Rare Human Nerve-Regrowth Evidence
- ARA-290 stands out because randomized, placebo-controlled human trials measured actual small-nerve-fiber regrowth.
- Its niche focus explains why it receives less attention than fat-loss or injury-recovery peptides.
How ARA-290 Separates Repair From EPO Doping
- Researchers separated EPO’s tissue-repair signaling from its red-blood-cell effects by creating an 11-amino-acid peptide targeting the innate repair receptor.
- This structural selectivity theoretically avoids EPO-linked hematocrit increases and clotting risk.
ARA-290 Targets Damaged Nerves Three Ways
- ARA-290 combines nerve protection, regrowth, and reduced macrophage-driven inflammation around damaged fibers.
- Researchers measured improvement through corneal confocal microscopy and skin-biopsy GAP43 staining.